Ancient American Genome Rekindles Legal Row
By Ewen Callaway,
Nature News
| 06. 18. 2015
Untitled Document
The genome of a famous 8,500-year-old North American skeleton, known as Kennewick Man, shows that he is closely related to Native American tribes that have for decades been seeking to bury his bones. The finding, reported today in Nature1, seems likely to rekindle a legal dispute between the tribes and the researchers who want to keep studying the skeleton. Yet it comes at a time when many scientists — including those studying Kennewick Man — are trying to move past such controversies by inviting Native Americans to take part in their research.
“The controversy has been painful for lots of people; tribal members and scientists as well,” says Dennis O’Rourke, a biological anthropologist at the University of Utah in Salt Lake City. “I think the results will add weight to repatriation claims because now claims of ancestry can at least to some degree be clarified,” he says.
Two teenagers discovered the bones in July 1996 near the shores of the Columbia River, near Kennewick, Washington. While trying to sneak into a hydroplane race, they noticed a...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...